Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection
Open Access
- 11 September 2003
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 349 (11), 1036-1046
- https://doi.org/10.1056/nejmoa021589
Abstract
We assessed the strategy of substituting nevirapine, efavirenz, or abacavir for a protease inhibitor in patients infected with human immunodeficiency virus type 1 (HIV-1) in whom virologic suppression had been achieved.Keywords
This publication has 36 references indexed in Scilit:
- A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsAIDS, 2003
- Switching Effective Antiretroviral Therapy: A ReviewClinical Infectious Diseases, 2002
- Low Risk of Treatment Failure after Substitution of Nevirapine for Protease Inhibitors among Human Immunodeficiency Virus–Infected Patients with Virus SuppressionThe Journal of Infectious Diseases, 2002
- Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral SuppressionClinical Infectious Diseases, 2002
- Efavirenz as a Substitute for Protease Inhibitors in HIV-1–Infected Patients With Undetectable Plasma Viral Load on HAART: A Median Follow-Up of 64 WeeksJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Switch to Efavirenz in a Protease Inhibitor-Containing RegimenHIV Research & Clinical Practice, 2001
- Substitution of a Nonnucleoside Reverse Transcriptase Inhibitor for a Protease Inhibitor in the Treatment of Patients with Undetectable Plasma Human Immunodeficiency Virus Type 1 RNAClinical Infectious Diseases, 2000
- Impact of Switching from Human Immunodeficiency Virus Type 1 Protease Inhibitors to Efavirenz in Successfully Treated Adults with LipodystrophyClinical Infectious Diseases, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsThe New England Journal of Medicine, 1999
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998